[The metabolic effects of isradipine, ramipril, Ednit and beta-adrenoblockers in patients with non-insulin-dependent diabetes mellitus and arterial hypertension].
The effect of isradepin, ramipril, ednyt, and beta-adrenoblockers on carbohydrate and lipid metabolism and free-radical oxidation in patients with insulin-independent diabetes mellitus was studied. Isradepin caused an increase in high-density lipoproteins (HDLP) in the blood serum and the content of esterified cholesterol in HDLP, and reduced the arterogenicity coefficient. Rampiril reduced the basal level of glycemia and insulin. Treatment with ednyt lead to increase in the content of HDLP and the content of free cholesterol in them. In the course of treatment isradepin normalized chemoluminescence of the serum and urine, rampiril that of serum, and beta-adrenoblockers the chemoluminescence of the blood. The favorable changes induced by the drugs under study allow them to be recommended for the treatment of arterial hypertension in patients with insulin-independent diabetes mellitus.
Morugova
T V
TV
Department of Endocrinology and Pharmacology, Bashkirian State Medical Institute, Ufa, Russia.
Lazareva
D N
DN
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D004656:Enalapril / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005609:Free Radicals / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism*; D017275:Isradipine / Q000008:administration & dosage / Q000494:pharmacology*; D008163:Luminescent Measurements; D008297:Male; D017257:Ramipril / Q000008:administration & dosage / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D005609:Free Radicals; D004656:Enalapril; D017257:Ramipril; D017275:Isradipine